You don't have javascript enabled. Good luck with that.
Skip to content

Hands-on education, diagnosing and treating CHE

The text 'Hands-on Education: Diagnosing and Treating CHE'. Graphic showing a person holding up their hand with visible eczema, alongside the text 'Hands-on Education: Diagnosing and Treating CHE'.

Actor portrayal. For illustrative purposes only.

THE CHALLENGE OF DIAGNOSING CHE

Patients with chronic hand eczema (CHE) may present with multiple subtypes and each subtype has unique immune signatures1,2

CHE is not just atopic dermatitis (AD) of the hands2

Venn diagram showing the overlap of eczema subtypes: irritant contact dermatitis, atopic dermatitis, and allergic contact dermatitis, with percentages of CHE cases.
aPercentages are from a CHE patient registry of 1163 patients across 95 centers in Germany.1

ETIOLOGICAL SUBTYPES INCLUDE4

MORPHOLOGICAL SUBTYPES INCLUDE4

More than 50% of patients with chronic hand eczema can have more than 1 additional diagnosed subtype.6

CHE PATHOPHYSIOLOGY

Close-up illustration showing cracked skin, representing the disruption of the skin barrier in chronic hand eczema.
Illustration depicting overlapping immune pathways involved in chronic hand eczema pathogenesis, driven by JAK-STAT signaling.

Discover the major impact of CHE on your patients

Illustration depicting overlapping immune pathways involved in chronic hand eczema pathogenesis, driven by JAK-STAT signaling.

WHEN THE STANDARD OF CARE IS NOT ENOUGH

Currently, topical corticosteroids (TCSs) are recommended as the short-term, first-line treatment for chronic hand eczema.3
 

Yet, for long-term intermittent use, their efficacy is limited, and TCSs have been associated with adverse events.2,3
 

Additionally, therapies targeting the type 2 immune response may not be effective in all CHE subtypes.2

Now, there is an FDA-approved treatment developed specifically for chronic hand eczema8

References: 1. Apfelbacher C, et al. Acta Derm Venereol. 2014;94(2):163-167. doi:10.2340/00015555-1632 2. Dubin C, et al. Ther Clin Risk Manag. 2020;16:1319-1332. doi:10.2147/TCRM.S292504 3. Diepgen TL, et al. J Dtsch Dermatol Ges. 2009;7(suppl 3):S1-S16. doi:10.1111/j.1610-0387.2009.07061.x 4. Thyssen JP, et al. Contact Dermatitis. 2022;86(5):357-378. doi:10.1111/cod.14035 5. Tauber M, et al. J Eur Acad Dermatol Venereol. 2024;38(6):997-998. doi:10.1111/jdv.20023 6. Agner T, et al. J Eur Acad Dermatol Venereol. 2015;29(12):2417-2422. doi:10.1111/jdv.13308 7. Lee GR, et al. Dermatol Ther. 2019;32(3):e12840. doi:10.1111/dth.12840. 8. ANZUPGO. Prescribing Information. LEO Pharma Inc.